# FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

> **NCT06917313** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 92 (estimated)

## Conditions studied

- Breast Cancer Early Stage Breast Cancer (Stage 1-3)

## Interventions

- **DRUG:** Fezolinetant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06917313
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917313, "FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06917313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*